by NImmune Biopharma | Apr 10, 2025 | Press Release
Download Press Release Omilancor is a once-daily, oral, best- and first-in-class therapy in Phase 3 clinical development for ulcerative colitis, with multiple I&I indications in progress New results to be presented in DDW elucidate omilancor’s path to patients and...
by NImmune Biopharma | Jan 13, 2025 | Press Release
Download Press Release First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral NIM-1324 treatment confirmed as well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 validated to engage LANCL2 in...
by NImmune Biopharma | Oct 23, 2024 | Press Release
Download Press Release Transaction is highly shareholder value accretive, enabling the potential acceleration of the global registration directed Phase 3 program in ulcerative colitis, the Phase 2 program in Crohn’s disease, and additional I&I indications Global...
by NImmune Biopharma | Oct 7, 2024 | Press Release
Download Press Release NIM-1324 validated as the first LANCL2 drug with therapeutic efficacy in systemic inflammation in three mouse models of lupus to support immune tolerance A mechanism of LANCL2 newly discovered in phagocytes that combines with established...
by NImmune Biopharma | Sep 16, 2024 | Press Release
Download Press Release BLACKSBURG, VA. – September 16, 2024 – NImmune Biopharma (“NImmune”), a Phase 3 precision inflammation & immunology (I&I) biopharmaceutical company that develops novel best-in-class biomarker-driven immunoregulatory...
by Dr. Josep Bassaganya-Riera | Sep 10, 2024 | Press Release
An original version of this article appeared in the Pharmaceutical Executive. The AI revolution is shaping numerous facets of our lives. While advancements by OpenAI and Anthropic plus NVIDIA’s market performance have commanded a significant portion of media...
